👋 Come join us for Investor Days in #Stavanger and #Trondheim in August! 📅 #Meet_the_Team

Spennende jobb på Farmasøytisk institutt: Associate Professor in Pharmaceutics (247419) | University of Oslo (jobbnorge.no)

Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results Clinical Cancer Research bit.ly/3CQk8gV

Livreddende teknologi! m.facebook.com/events/7405267…

Viktig tema i dagens verden! m.facebook.com/events/2931113…

Want to learn more about our CEO? Read the portrait interview with Carlos de Sousa in Finansavisen this Sat July 8 ☀️ #SummerReading #biotech #CEO #CancerResearch #Immunotherapy finansavisen.no/helse/2023/07/…

Vi tok debatten, realfagskrisen! Vi har en rekrutteringskrise til realfagene. Jan Tore Sanner mente at dette er den viktigste debatten ila Arendalsuka. Hvordan skal vi klare å bekle det fremtidige arbeidslivet innenfor fornybar energi, Ikt, helseteknologi mm.

We are looking forward to our Q2 2023 presentation tomorrow at 14:00 CEST. Questions to the management can be submitted throughout the event or by email to [email protected] Tune in to the webcast here: channel.royalcast.com/hegnarmedia/#!… #biotech #Q2_2023 #earnings

Spennende jobb for deg som vil gjøre en forskjell: jobbnorge.no/en/available-j…

Lytt & lær! 💫🇳🇴 #kreftforskning #biotech #immunterapi #kreftvaksiner

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma, Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine: No confirmed patient deaths in cohort 1 between the 3-year and 4-year follow-up bit.ly/48Rrb7E

Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma bit.ly/3QiYABc

medwatch.no/nyheter/legemi… 💫

Gratulerer!

Great news from Ultimovacs!

Ultimovacs has reported positive phase II overall survival data with its #cancervaccine candidate UV1 in #mesothelioma. BioStock spoke with Director Medical Affairs Espen Basmo Ellingsen to better understand the significance of these results. #biotech biostock.se/en/2023/10/ult…

Oral session 15:15 at Salamanca Aud. Åslaug Helland #ESMO23 LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant #mesothelioma

Som tidligere annonsert så kommer Åslaug Helland i podkasten tirsdag - & nå kan vi melde at CMO Jens Bjørheim i Ultimovacs også blir med. Tema er NIPU-dataene og hva de betyr for kreftpasienter, og hva selskapet tenker videre nå. Send oss spørsmål:)

Det norske kreftvaksineselskapet sikrer seg avlesing i første halvdel av 2024 for INITIUM-studien. via MedWatch News medwatch.no/nyheter/legemi…

Vårt porteføljeselskap ArtBio henter nær 1 milliard kroner fra nye og eksisterende investorer, blant annet Third Rock Ventures #radiofarmasi #prostatakreft medwatch.no/nyheter/legemi…